New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
07:08 EDTMYOSMYOS announces agreement with Cloud Pharmaceuticals
MYOS announced that it has entered into a research and development agreement with Cloud Pharmaceuticals. The research and development program will focus on product candidates related to the inhibition of targets in the myostatin regulatory pathway as well as inflammatory mediators associated with sarcopenia and cachexia. Under the terms of the agreement MYOS will have proprietary rights to the design and structure of any small molecules developed for the muscle-health treatment market.
News For MYOS From The Last 14 Days
Check below for free stories on MYOS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
08:09 EDTMYOSMYOS appoints Douglas Weekes as Chief Commercial Officer
MYOS announced that it has appointed Douglas Weekes as Chief Commercial Officer. Weekes will lead the company's marketing, sales and product development of a portfolio of commercial products derived from the first clinically proven natural myostatin inhibitor, Fortetropin.
July 25, 2014
08:13 EDTMYOSMYOS extends agreement for Fortetropin
MYOS announced that it has signed an extension of its supply agreement with Deutsches Institut fuer Lebensmitteltechnik e.V, or DIL, the German Institute for Food Technologies, for the continued manufacturing and supply of Fortetropin, the first clinically proven natural myostatin inhibitor. DIL Under the terms of the agreement, DIL will manufacture and supply Fortetropin exclusively for MYOS through the end of 2016 with a significant cost-savings component. The supply relationship maintains the stable, world-class manufacturing and supply of Fortetropin, the primary proprietary ingredient in MYOS' core muscle health bionutrition supplement products. Fortetropin is produced using a proprietary method in accordance with the highest industry standards, incorporating DIL's state of the art High Pressure Pasteurization, or HPP, technology for preserving the high quality freshness of the natural ingredients. Use of the proprietary manufacturing process at DIL's cutting edge facilities ensures the continued efficacy and quality of Fortetropin. The Supply Agreement extension also requires ongoing adherence to the highest levels of product testing.
July 24, 2014
08:21 EDTMYOSMYOS receives patent allowance in U.S.
MYOS announced that it recently received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Serial No. 13/765,340 covering the Company's proprietary methods of manufacturing Fortetropin, the first clinically proven natural myostatin inhibitor. Upon issuance, the U.S. Patent entitled, "Process for Producing a Composition Containing Active Follistatin," will provide intellectual property protection for making the key ingredient in MYOS' core commercial muscle health products and carries a patent term through early 2033.
July 22, 2014
08:11 EDTMYOSMYOS reports positive top-line clinical study results for Fortetropin
Subscribe for More Information
July 17, 2014
07:08 EDTMYOSMYOS announces agreement with Cloud Pharmaceuticals
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use